Did You Know...
...that the Slinky toy was the result of a failed attempt by engineer Richard James to produce an antivibration device for ship instruments? His goal was to develop a spring that would instantaneously counterbalance the wave motion that rocks a ship at sea. Instead, he developed the Slinky.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183340 | GLP-1 pegylated compounds The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1... | 05/22/2012 |
| 8158579 | Fusion protein of an exendin to modified transferrin The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exe... | 04/17/2012 |
| 8114959 | Stabilized pharmaceutical peptide compositions Method for increasing the shelf-life of a pharmaceutical composition comprising a glucagon-like peptide which is prepared from a peptide product that has been dried at a pH above neutral pH. ... | 02/14/2012 |
| 8093206 | Methods involving long lasting synthetic exendin-4 peptide conjugates Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to... | 01/10/2012 |
| 8084414 | Methods involving long lasting synthetic exendin-4-peptide conjugates Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to... | 12/27/2011 |
| 8080516 | Long lasting synthetic exendin-4 peptide conjugates Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to... | 12/20/2011 |
| 7994121 | Stable analogs of peptide and polypeptide therapeutics The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. ... | 08/09/2011 |
| 7989585 | Chronic treatment regimen using glucagon-like insulinotropic peptides The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. ... | 08/02/2011 |
| 7981861 | Method of performing angioplasty with a GLP-1 molecule The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-a... | 07/19/2011 |
| 7893017 | Protracted GLP-1 compounds Novel protracted GLP-1 compounds and therapeutic uses thereof. ... | 02/22/2011 |
| 7888317 | Glucagon-like peptide-2 and its therapeutic use Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation ... | 02/15/2011 |
| 7867972 | Fusion protein of exendin-4 to a transferrin (Tf) polypeptide The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exe... | 01/11/2011 |
| 7847061 | Treatment of short bowel syndrome patients with colon-in-continuity Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. ... | 12/07/2010 |
| 7781567 | Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides The invention provides methods for making peptides from a polypeptide containing at least one copy of the peptide using clostripain to excise the peptide from the polypeptide. The methods enable the use of a single, highly efficient enzymatic cleavage to produce any... | 08/24/2010 |
| 7737251 | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflamma... | 06/15/2010 |
| 7691963 | Exendins and exendin agonists modified with polyamino acids Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, polyamino acids, polyethylene glycol polymers, and related formulations and dosages and methods of administration th... | 04/06/2010 |
| 7589169 | Compositions for treatment with glucagon-like peptide, and methods of making and using the same In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and GLP-1. ... | 09/15/2009 |
| 7557183 | Polyethylene glycol linked GLP-1 compounds The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGyla... | 07/07/2009 |
| 7538185 | Glucagon-like peptide-1 analogs with long duration of action Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the f... | 05/26/2009 |
| 7538186 | Exendins and exendin agonists modified with polyamino acids Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more molecular weight increasing compounds, for example, polyamino acids, polyethylene glycol polymers, and related formulations and dosages and methods of administration th... | 05/26/2009 |
| 7521527 | GLP-1 pharmaceutical compositions The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. ... | 04/21/2009 |
| 7442680 | Inotropic and diuretic effects of GLP-1 and GLP-1 agonists Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed.... | 10/28/2008 |
| 7442682 | Transepithelial delivery of peptides with incretin hormone activities Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incr... | 10/28/2008 |
| 7423019 | Agent for inducing conversion of intestinal cells into insulin-producing cells and antidiabetic drug A partial peptide of a preproglucagon peptide comprising at least the amino acid sequence at positions 92-97 of a preproglucagon peptide is used as an effective ingredient of an antidiabetic drug. ... | 09/09/2008 |
| 7411039 | GLP-2 compounds, formulations, and uses thereof The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprisi... | 08/12/2008 |
| 7399745 | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders. ... | 07/15/2008 |
| 7371721 | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes The present invention relates to methods for prevention and treatment of bone-related disorders and calcium homeostasis related syndromes using a GLP-2 molecule or GLP-2 activator either alone or in combination with another therapeutic. The present invention also en... | 05/13/2008 |
| 7368427 | GLP-1 analogues The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. ... | 05/06/2008 |
| 7329725 | Phage displayed Trp cage ligands Trp cage binding domain polypeptides are disclosed. The Trp cage binding domains have the generic formulas of SEQ ID NO: 2, 7, 10 or 11. They can be efficiently produced and screened using phage display technology. ... | 02/12/2008 |
| 7323543 | Multiple agent diabetes therapy A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin ana... | 01/29/2008 |
| 7291594 | GLP-1 derivative and preparation thereof absorbable via mucous membrane A GLP-1 derivative is provided including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is ... | 11/06/2007 |
| 7273921 | Method for producing acylated peptides The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent. ... | 09/25/2007 |
| 7271149 | GLP-1 fusion proteins The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other con... | 09/18/2007 |
| 7268213 | Analogues of GLP-1 The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. ... | 09/11/2007 |
| 7265087 | Exendin improves β-cell response in subjects with impaired glucose tolerance A composition for the treatment of impaired glucose tolerance (IGT) including a compound which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier. The amount of the compound present is an effective amount to improve pancreatic β-cell sens... | 09/04/2007 |
| 7259234 | Stable analogs of peptide and polypeptide therapeutics The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. ... | 08/21/2007 |
| 7259136 | Compositions and methods for treating peripheral vascular disease The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom. ... | 08/21/2007 |
| 7259233 | Chronic treatment regimen using glucagon-like insulinotropic peptides The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range. ... | 08/21/2007 |
| 7235628 | Analogues of GLP-1 The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful thereof comprising said analogues. ... | 06/26/2007 |
| 7235627 | Derivatives of GLP-1 analogs The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant. ... | 06/26/2007 |
